Joshua S. Boger Sells 6,500 Shares of Vertex Pharmaceuticals Inc. (VRTX) Stock
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $81.14, for a total value of $527,410.00. Following the completion of the sale, the director now directly owns 274,725 shares in the company, valued at approximately $22,291,186.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) traded up 0.22% on Friday, reaching $80.74. The company’s stock had a trading volume of 939,642 shares. Vertex Pharmaceuticals Inc. has a 52-week low of $75.90 and a 52-week high of $134.71. The firm has a 50 day moving average of $90.80 and a 200 day moving average of $89.74. The company’s market cap is $20.01 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.03. Vertex Pharmaceuticals had a negative return on equity of 12.34% and a negative net margin of 17.77%. The company earned $431.61 million during the quarter, compared to analysts’ expectations of $428.08 million. During the same quarter in the previous year, the company posted ($0.54) earnings per share. The business’s revenue was up 159.9% on a year-over-year basis. Analysts predict that Vertex Pharmaceuticals Inc. will post $0.89 earnings per share for the current year.
Large investors have recently modified their holdings of the company. Commonwealth Equity Services Inc boosted its stake in shares of Vertex Pharmaceuticals by 23.7% in the first quarter. Commonwealth Equity Services Inc now owns 6,999 shares of the pharmaceutical company’s stock worth $556,000 after buying an additional 1,342 shares in the last quarter. Virginia Retirement System purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $317,000. NN Investment Partners Holdings N.V. purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $2,334,000. Aviva PLC boosted its stake in shares of Vertex Pharmaceuticals by 1.1% in the first quarter. Aviva PLC now owns 135,620 shares of the pharmaceutical company’s stock worth $10,780,000 after buying an additional 1,456 shares in the last quarter. Finally, Credit Agricole S A boosted its stake in shares of Vertex Pharmaceuticals by 2.2% in the first quarter. Credit Agricole S A now owns 40,548 shares of the pharmaceutical company’s stock worth $3,222,000 after buying an additional 857 shares in the last quarter. Institutional investors own 96.19% of the company’s stock.
A number of equities research analysts have recently issued reports on VRTX shares. Citigroup Inc. started coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 13th. They set a “market perform” rating on the stock. They noted that the move was a valuation call. Raymond James Financial Inc. began coverage on Vertex Pharmaceuticals in a report on Tuesday, September 13th. They set a “market perform” rating on the stock. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 27th. Jefferies Group reiterated a “buy” rating and set a $107.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, September 15th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 5th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $117.60.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.